Navigation Links
Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
Date:3/30/2009

- U.S. FDA approves Intercell's first marketed product, a new vaccine against Japanese Encephalitis for travelers and military personnel

- Commercial product launch in the U.S. planned for Q2 2009

VIENNA, March 30 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that the U.S. Food and Drug Administration (FDA) approved IXIARO(R), a new vaccine for the prevention of Japanese Encephalitis (JE). The initial target for use of Intercell's vaccine - the only such product currently manufactured for the U.S. market - will be adult travelers and military personnel who visit or are deployed to affected countries, including India, China, and other parts of Asia.

"This approval is a major achievement for Intercell, and it marks a significant milestone in this company's history. The approval of IXIARO by the FDA - part of a regulatory process that included parallel filings in Europe and Australia - puts us in a select group of biotechnology companies with both an FDA-approved product and an outstanding pipeline of promising vaccine candidates," said Intercell's Chief Executive Officer, Gerd Zettlmeissl. "With this decision, Americans - both civilians and military personnel - will have an efficacious and safe way to protect themselves from the devastating and deadly effects of Japanese Encephalitis."

JE is a deadly infectious disease found mainly in Asia. Approximately 30,000 to 50,000 cases of JE are reported in Asia each year, and the actual number of cases are likely much higher due to underreporting in rural areas. JE is fatal in approximately 30 percent of those who show symptoms and leaves half of survivors with permanent brain damage. As there is no specific treatment for JE, vaccination is the only highly effective protection for the millions of travelers and military personnel who live in or travel to areas where the virus circulates.

Intercell's vaccine is a purified, i
'/>"/>

SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
2. Iomai Stockholders Approve Merger With Intercell Subsidiary
3. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
4. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
5. Spherix Announces 2008 Financial Results
6. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing
7. SENOMYX ANNOUNCES EXTENSION OF ITS COLLABORATION WITH CAMPBELL SOUP COMPANY
8. Warner Chilcott Announces NDA Submission for Low Dose Oral Contraceptive
9. Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders
10. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
11. International Isotopes Inc. Announces Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has filed its Annual Report on Form ... filed Form 20-F includes audited financial statements for the ... can be accessed by visiting the U.S. Securities and ...
(Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... BERKELEY HEIGHTS, N.J., June 5 Genta,Incorporated (OTC Bulletin ... into definitive agreements with institutional and accredited,investors to ... in,aggregate up to $40 million in gross proceeds ... $20 million of Notes is expected to take ...
... Life Sciences Inc.,(TSX: PLI) ("ProMetic") announced today that ... earlier this year with the Wuhan,Institute of Biological ... ("CNBG") was held on Wednesday, June 4, 2008 ... were CNBG,s President and Chief Executive,Officer Ms. Lifeng ...
... 2009 and ... ... serve as an ideal launching pad that positions the company for,new ... Monsanto,s executive vice president of global,commercial, will tell investors today at ...
Cached Biology Technology:Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 2Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 3Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs 4Official Signing Ceremony for WIBP Strategic Alliance 2Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 2Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 3Monsanto's Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America 4
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. ... human interface solutions, today announced that Huawei has ... touchscreen solution for its stylish smartwatch. Huawei chose ... proven reliability, low power and highly responsive human ... finger. Huawei designers also required a classic round ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... that can sail throughout the body via the bloodstream ... and ferry their cargo of anti-cancer drugs and markers ... In a forthcoming issue of the Germany-based chemistry ... Diego, UC Santa Barbara and MIT report that their ...
... this goal, scientists at the OU Cancer Institute have found ... they can target the cells and kill them, keeping cancer ... of Oklahoma led by Courtney Houchen, M.D., and Shrikant Anant, ... cells. Until now, researchers knew of proteins that appeared in ...
... -- What,s the worst that could happen after eating a ... But for up to a million women in the ... have a chronic bladder condition that causes pelvic pain. Spicy ... can cause a flare in their symptoms and intensify the ...
Cached Biology News:Researchers develop nano-sized 'cargo ships' to target and destroy tumors 2Researchers develop nano-sized 'cargo ships' to target and destroy tumors 3Researchers develop nano-sized 'cargo ships' to target and destroy tumors 4The pepperoni pizza hypothesis 2The pepperoni pizza hypothesis 3
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
SHEEP ANTI DEHYDROEPIANDROSTERONE...
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Biology Products: